To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.
Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.
The Quirem team will attend ECIO in Nice from April 26-29 2020.
SIRT in three steps
Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:
News and events
Radboud university medical center and Quirem Medical today signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres (holmium-166 microspheres). Enhanced cooperation should improve the treatment
In their study, Smits et al. showed that QuiremScout® is a superior predictor of intrahepatic dose distribution compared to Tech-99m-MAA. The results of their study were published online on the 9th of August 2019 in
Deventer, August 7, 2019 – Today a first clinical QuiremScout® patient procedure took place with radioactive holmium-166 microspheres that were activated at the NRG reactor in Petten, the Netherlands. QuiremScout® is an innovative product for
What our customers say